[go: up one dir, main page]

MX2009003469A - Uso de farmacos que inducen hipotermia para el tratamiento de isquemia. - Google Patents

Uso de farmacos que inducen hipotermia para el tratamiento de isquemia.

Info

Publication number
MX2009003469A
MX2009003469A MX2009003469A MX2009003469A MX2009003469A MX 2009003469 A MX2009003469 A MX 2009003469A MX 2009003469 A MX2009003469 A MX 2009003469A MX 2009003469 A MX2009003469 A MX 2009003469A MX 2009003469 A MX2009003469 A MX 2009003469A
Authority
MX
Mexico
Prior art keywords
hypothermia
inducing drugs
treat ischemia
capsaicinoid
hypothermia inducing
Prior art date
Application number
MX2009003469A
Other languages
English (en)
Inventor
Uno Jakob Weber
Jacob Gotfredsen
Original Assignee
Neurokey As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurokey As filed Critical Neurokey As
Publication of MX2009003469A publication Critical patent/MX2009003469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a la inducción de la hipotermia en humanos en una forma predecible y sensibles a la dosis mediante el uso de una composición farmacéutica que comprende agonistas de receptores vaniloides, agonistas capsaicinoides o tipo capsaicinoide capaces de inducir la hipotermia, beneficiando en consecuencia a pacientes que sufren enfermedades caracterizadas por la anoxina de tejidos.
MX2009003469A 2006-10-04 2007-10-04 Uso de farmacos que inducen hipotermia para el tratamiento de isquemia. MX2009003469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200601289 2006-10-04
DKPA200700335 2007-03-06
PCT/DK2007/050137 WO2008040360A2 (en) 2006-10-04 2007-10-04 Use of hypothermia inducing drugs to treat ischemia

Publications (1)

Publication Number Publication Date
MX2009003469A true MX2009003469A (es) 2009-05-28

Family

ID=39199950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003469A MX2009003469A (es) 2006-10-04 2007-10-04 Uso de farmacos que inducen hipotermia para el tratamiento de isquemia.

Country Status (11)

Country Link
US (1) US20090197966A1 (es)
EP (1) EP2076255A2 (es)
JP (1) JP2010505774A (es)
KR (1) KR20090064435A (es)
AU (1) AU2007304588A1 (es)
BR (1) BRPI0719203A2 (es)
CA (1) CA2664399A1 (es)
IL (1) IL197553A0 (es)
MX (1) MX2009003469A (es)
RU (1) RU2009116455A (es)
WO (1) WO2008040360A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083807A2 (en) * 2006-10-04 2009-08-05 Neurokey A/S Use of a combination of hypothermia inducing drugs
WO2009071096A2 (en) * 2007-12-05 2009-06-11 Neurokey A/S Combination of medical and physical cooling treatment of ischemic effects
WO2009124553A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
WO2009124551A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
WO2010015965A2 (en) * 2008-08-04 2010-02-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
WO2010015260A2 (en) * 2008-08-07 2010-02-11 Neurokey A/S Administration by infusion for the treatment of ischemic effects
US8604053B2 (en) 2008-10-17 2013-12-10 Abbvie Inc. TRPV1 antagonists
EP2352727A1 (en) 2008-10-17 2011-08-10 Abbott Laboratories Trpv1 antagonists
NZ604498A (en) 2010-05-26 2014-10-31 Neurophyxia B V 2-iminobiotin formulations and uses thereof
US8802711B2 (en) 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
AU2016372396B2 (en) 2015-12-16 2022-04-14 Neurophyxia B.V. 2-iminobiotin for use in the treatment of brain cell injury
US10565238B2 (en) * 2017-08-08 2020-02-18 Sap Se Address applications using address deliverability metrics
CN109833318A (zh) * 2017-11-29 2019-06-04 中国辐射防护研究院 一种亚低温小鼠动物模型的制备方法
WO2020061315A1 (en) * 2018-09-20 2020-03-26 University Of Miami Materials and methods for inducing therapeutic hypothermia in a mammalian subject

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63287724A (ja) * 1987-05-20 1988-11-24 Tsumura & Co 脳機能改善剤
US5840762A (en) * 1996-01-12 1998-11-24 Genderm Corporation Method for the treatment of cardiac arrhythmias and shortening of action potential duration
WO1999004783A1 (en) * 1997-07-25 1999-02-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Composition for protection from damage by ischemia
US20010010919A1 (en) * 1998-10-13 2001-08-02 David K. Grandy Opioid antagonists and methods of their use
CA2286442A1 (en) * 1999-10-15 2001-04-15 Universite De Montreal Compositions for increasing the concentration of cannabinoids as vasodilators and cardioprotectors againts ischaemia
AU2002236438A1 (en) * 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
US20020077322A1 (en) * 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions
US6872748B2 (en) * 2001-09-27 2005-03-29 Digital Biotech Co., Ltd. Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same
US7319090B2 (en) * 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
PT1572632E (pt) * 2002-12-09 2008-09-19 Xention Ltd Derivados de tetra-hidro-naftaleno como antagonistas do receptor vanilóide
CA2543166A1 (en) * 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. Ph sensitive prodrugs of 2,6-diisopropylphenol
CA2654026A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia

Also Published As

Publication number Publication date
EP2076255A2 (en) 2009-07-08
WO2008040360A3 (en) 2008-05-29
KR20090064435A (ko) 2009-06-18
RU2009116455A (ru) 2010-11-10
US20090197966A1 (en) 2009-08-06
JP2010505774A (ja) 2010-02-25
AU2007304588A1 (en) 2008-04-10
IL197553A0 (en) 2009-12-24
WO2008040360A2 (en) 2008-04-10
CA2664399A1 (en) 2008-01-10
BRPI0719203A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
MX2009003469A (es) Uso de farmacos que inducen hipotermia para el tratamiento de isquemia.
WO2008040361A3 (en) Use of a combination of hypothermia inducing drugs
WO2009124552A3 (en) Use of a combination of hypothermia inducing drugs
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
WO2010015260A3 (en) Administration by infusion for the treatment of ischemic effects
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
IL195560A0 (en) Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
IN2014DN09571A (es)
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
EE05761B1 (et) Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks
CL2011000061A1 (es) Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
CL2007002643A1 (es) Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan
MX2019007619A (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.
CL2008003024A1 (es) Compuestos derivados de alquilsulfonilbenzotiazol, moduladores del receptor de grelina; formulacion farmaceutica; y uso para el tratamiento de obesidad o sobrepeso, diabetes, sindrome metabolico, entre otras.
WO2009124553A3 (en) Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2009071096A3 (en) Combination of medical and physical cooling treatment of ischemic effects
WO2009071094A3 (en) Combination treatment of ischemic effects
BRPI0809837A2 (pt) "composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.
EA200702318A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса
EP2323656A4 (en) PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST